Cite

HARVARD Citation

    Naganuma, M. et al. (2022). Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. Journal of gastroenterology and hepatology. 37 (1), pp. 81-88. [Online]. 
  
Back to record